Viewing Study NCT03184558

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:22 AM
Ignite Modification Date: 2026-01-25 @ 4:26 AM
Study NCT ID: NCT03184558
Status: TERMINATED
Last Update Posted: 2021-11-09
First Post: 2017-05-30
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
Sponsor: BerGenBio ASA
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Triple Negative Breast Cancer View
None Inflammatory Breast Cancer Stage IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None bemcentinib View
None TNBC View
None pembrolizumab View
None Keytruda View
None BGB324 View